Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
Saved in:
| Title: | Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. |
|---|---|
| Authors: | Jackson CG, Sharples K, Thompson PI, O'Donnell A, Robinson BA, Perez DJ, Adams J, Isaacs R, Deva S, Hinder VA, Findlay MP; Cancer Trials New Zealand, University of Auckland, Level 1, Building 505, 85 Park Road, Grafton, Auckland, New Zealand. mp.findlay@auckland.ac.nz. |
| Source: | BMC cancer [BMC Cancer] 2014 Oct 02; Vol. 14, pp. 737. Date of Electronic Publication: 2014 Oct 02. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
